{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:26:35Z","timestamp":1787757995016,"version":"build-2784847793"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.canrad.2026.104857","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:45:36Z","timestamp":1786117536000},"page":"104857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The place of radiotherapy in the treatment of inflammatory breast cancer: Practical questions and responses"],"prefix":"10.1016","volume":"30","author":[{"given":"Pierre","family":"Loap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlia","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.canrad.2026.104857_bib0150","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/jnci\/dji172","article-title":"Trends in Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program at the National Cancer Institute","volume":"97","author":"Hance","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.canrad.2026.104857_bib0155","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/annonc\/mdq345","article-title":"International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment","volume":"22","author":"Dawood","year":"2011","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.canrad.2026.104857_bib0160","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2414859","article-title":"Omitting regional nodal irradiation after response to neoadjuvant chemotherapy","volume":"392","author":"Mamounas","year":"2025","journal-title":"N Engl J Med"},{"issue":"10416","key":"10.1016\/j.canrad.2026.104857_bib0165","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/S0140-6736(23)01082-6","article-title":"Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14,324 women in 16 trials","volume":"402","author":"Taylor","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.canrad.2026.104857_bib0170","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(20)30472-1","article-title":"Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922\/10925): 15-year results of a randomised, phase 3 trial","volume":"21","author":"Poortmans","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104857_bib0175","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/jamaoncol.2021.6036","article-title":"Effect of elective internal mammary node irradiation on disease-free survival in women with node-positive breast cancer: a randomized phase 3 clinical trial","volume":"8","author":"Kim","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2026.104857_bib0180","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(18)30813-1","article-title":"Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial","volume":"20","author":"Wang","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2026.104857_bib0185","doi-asserted-by":"crossref","first-page":"S309","DOI":"10.1016\/j.annonc.2024.08.174","article-title":"Locoregional hypo vs. normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase III Unicancer trial","volume":"35","author":"Rivera","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2026.104857_bib0190","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00066-025-02454-4","article-title":"Genomic analysis of radiosensitivity in breast cancer: identifying pathological determinants and assessing genomic-adjusted radiation dose (GARD) for personalized dose escalation","volume":"202","author":"Loap","year":"2026","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"10.1016\/j.canrad.2026.104857_bib0195","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.ijrobp.2019.12.006","article-title":"The limits of the linear quadratic (LQ) model for late cardiotoxicity prediction: example of hypofractionated rotational intensity modulated radiation therapy (IMRT) for breast cancer","volume":"106","author":"Loap","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.canrad.2026.104857_bib0200","doi-asserted-by":"crossref","first-page":"101384","DOI":"10.1016\/j.adro.2023.101384","article-title":"Tolerance of concurrent adjuvant radiotherapy and pembrolizumab for triple negative breast cancer: real life experience","volume":"9","author":"Tison","year":"2023","journal-title":"Adv Radiat Oncol"},{"issue":"19","key":"10.1016\/j.canrad.2026.104857_bib0205","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.3390\/cancers13194790","article-title":"Pertuzumab and trastuzumab combination with concomitant locoregional radiotherapy for the treatment of breast cancers with HER2 receptor overexpression","volume":"13","author":"Aboudaram","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.canrad.2026.104857_bib0210","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/COC.0000000000001131","article-title":"Concurrent use of radiotherapy and ribociclib: preliminary results and review of the literature","volume":"47","author":"Bouziane","year":"2024","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2026.104857_bib0215","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41416-020-0957-9","article-title":"Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature","volume":"123","author":"Beddok","year":"2020","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.canrad.2026.104857_bib0220","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000538847","article-title":"Concurrent use of abemaciclib and radiotherapy in metastatic breast cancer patients: a single-center experience","volume":"69","author":"Ippolito","year":"2024","journal-title":"Chemotherapy"},{"issue":"2","key":"10.1016\/j.canrad.2026.104857_bib0225","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1016\/j.ijrobp.2024.07.755","article-title":"Safety and feasibility of concurrent abemaciclib and postoperative radiotherapy for breast cancer: a real-world analysis","volume":"120","author":"Xuan","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.canrad.2026.104857_bib0230","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ijrobp.2017.04.030","article-title":"A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer","volume":"99","author":"Woodward","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.canrad.2026.104857_bib0235","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ijrobp.2025.05.013","volume":"123","author":"Loap","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10.1016\/j.canrad.2026.104857_bib0240","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/COC.0000000000000769","article-title":"Adjuvant trastuzumab emtansine (T-DM1) and concurrent radiotherapy for residual invasive HER2-positive breast cancer: single-center preliminary results","volume":"43","author":"Zolcs\u00e1k","year":"2020","journal-title":"Am J Clin Oncol"},{"issue":"7\u20138","key":"10.1016\/j.canrad.2026.104857_bib0245","doi-asserted-by":"crossref","first-page":"104757","DOI":"10.1016\/j.canrad.2025.104757","article-title":"Guidelines about radiotherapy and oncologic systemic treatments: stop or continue?","volume":"29","author":"Buchalet","year":"2025","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104857_bib0250","doi-asserted-by":"crossref","first-page":"103756","DOI":"10.1016\/j.clon.2025.103756","article-title":"Survival and prognostic factors in nonmetastatic chemorefractory inflammatory breast cancer: a comprehensive population-based study","volume":"39","author":"Loap","year":"2025","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"10.1016\/j.canrad.2026.104857_bib0255","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.radonc.2012.01.008","article-title":"Effect of preoperative rescue concomitant FUN\/XUN-based chemoradiotherapy for neoadjuvant chemotherapy-refractory breast cancer","volume":"103","author":"Bourgier","year":"2012","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2026.104857_bib0260","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ijrobp.2017.04.030","article-title":"A phase II study of preoperative capecitabine and concomitant radiation in women with advanced breast cancer","volume":"99","author":"Woodward","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.canrad.2026.104857_bib0265","doi-asserted-by":"crossref","first-page":"735","DOI":"10.4329\/wjr.v8.i8.735","article-title":"Helical tomotherapy and volumetric modulated arc therapy: new therapeutic arms in the breast cancer radiotherapy","volume":"8","author":"Lauche","year":"2016","journal-title":"World J Radiol"},{"issue":"6\u20137","key":"10.1016\/j.canrad.2026.104857_bib0270","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.canrad.2020.07.001","article-title":"Radio-induced cardiotoxicity: from physiopathology and risk factors to adaptation of radiotherapy treatment planning and recommended cardiac follow-up","volume":"24","author":"Kirova","year":"2020","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104857_bib0275","doi-asserted-by":"crossref","first-page":"103121","DOI":"10.1016\/j.critrevonc.2020.103121","article-title":"Cardiotoxicity in breast cancer patients treated with radiation therapy: from evidences to controversies","volume":"156","author":"Loap","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.canrad.2026.104857_bib0280","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.clon.2012.07.012","article-title":"Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart","volume":"25","author":"Appelt","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"4","key":"10.1016\/j.canrad.2026.104857_bib0285","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2019.03.029","article-title":"Photons without bolus versus electrons with bolus after upfront mastectomy without immediate reconstruction in breast cancer patients","volume":"104","author":"Boulle","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.canrad.2026.104857_bib0290","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00066-025-02411-1","article-title":"Proton therapy in young breast cancer patients with germline TP53 and ATM mutations: a case series","volume":"202","author":"Loap","year":"2026","journal-title":"Strahlenther Onkol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321826000600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321826000600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:01:12Z","timestamp":1787756472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321826000600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1278321826000600"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2026.104857","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The place of radiotherapy in the treatment of inflammatory breast cancer: Practical questions and responses","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2026.104857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104857"}}